The portfolio, right now

Figures below are placeholders pending the live metrics feed described in the engineering note near the bottom of this page — shown as "—" rather than a fabricated number, per our own integrity policy.

Ventures operational

— / 17

Aggregate uptime (30d)

—

Studies in flight

—

External grants disbursed

—

Founding Donor Circle seats

— / 100

Restricted funds raised (Tranche 1)

—

Integrity markers

• We publish null results from validation studies, not only positive ones.
• Seven ventures our own review killed are listed below with the reason each was stopped, rather than quietly dropped.
• Internal venture tiering (Strong / Viable / archived) never appears differently in public materials than it does internally — no separate "investor narrative."
• A Scientific Advisory Board with independent external members governs the grants program.
• Engineering and security review reports (the “gate report” archive) will be published here as they are finalised. None is published yet — this line will say otherwise only when that changes.

Ventures we stopped

Seven. Each was evaluated, built or scoped, and then killed by our own review — with the reason recorded at the time, not written afterwards. They are listed here because a portfolio that only ever shows its survivors is not showing you its judgement.

Reasons are quoted from the internal registry as written on the day each venture was retired.

Venture	What it was	Why we stopped
Meridian	IP-portfolio tooling	Pivoted to a low-ceiling SaaS with no strategic asset. We would reverse the pivot if a real IP asset emerged.
Coulomb	Home tDCS therapeutic	Pivoted from a therapeutic to niche research SaaS — a boring pivot that kept the plumbing and dropped the science.
Tessera	Pharmacogenomic reporting	Redundant with Ladder, which surfaces the same genetics at the point of prescribing instead of in a separate report.
Kelp	Microbiome research data commons	Small market, unclear moat. Reopen if a landmark causal microbiome–ADHD study lands.
Clarify	Clinical documentation assistant	Structural: a feature, not a platform. Ambient scribes will absorb the workflow.
Omega-3	Direct-to-consumer supplementation	No defensible moat against commodity generics.
VR Assessment	Virtual-reality cognitive assessment	The cognitive-training transfer problem is a scientific wall. Akili spent $500M+ establishing that digital therapeutics for ADHD lack a business model; we did not need to repeat it.

An eighth venture, Titrately, is not counted here: it was renamed and rebuilt as Ladder, not stopped. Ladder's first migration still creates the database roles under Titrately's name, which is how directly one became the other.

What's been funded so far

A donor roll (opt-in — anonymity honored on request) and a per-fund breakdown of restricted-fund utilization against the milestone plan will populate here once the donor CRM is live. Until then, the quarterly draw-down of the founder's own endowment against the milestone table in PRODUCTION_COMPLETION_PLAN.md §10.1 is the first entry in this ledger, by design — the founder's money is held to the same accountability standard external donors will expect.

Transparency reports & gate-report archive

The first annual transparency report (finances by fund, study readouts including negatives, security-posture summary) is scheduled for publication once Wave 1 has been live for a full reporting cycle. Engineering and security gate reports for each venture will be linked here individually as they're finalized for public release.

No reports are published yet — this section will list them by date and venture once available.